The global CDMO market includes a small group of very large platforms with sites on several continents, and a much deeper bench of specialist and regional manufacturers, many of them in India and the wider Asia region. But the largest CDMO is rarely the right CDMO. For most buyers sourcing finished formulations or APIs, the decision comes down to dosage-form fit, regulatory track record in your target market, and available capacity — not global revenue rank. This guide explains how the CDMO market is structured, how the India and Asia landscape fits in, and the due-diligence checklist that separates a working partnership from an expensive mistake.
The mistake that costs the most — and it happens before the CDMO is chosen
In 25 years of international business development and licensing, the pattern I see most often is not that a buyer selects a poor manufacturer. It is that they approach manufacturers before they have answered three questions themselves. The result is months of circular discussion, quotations that cannot be compared against each other, and occasionally a signed agreement for a product that was never the right one for the market.
1. The regulatory pathway is undefined. A buyer knows the market they want to enter but has not decided how the product will be registered there — which dossier format applies, whether bioequivalence data is required, whether the reference product is registered locally, whether an existing dossier can be transferred or a fresh filing is needed. Without that decided, no manufacturer can quote meaningfully, because the work varies enormously depending on the answer. Two CDMOs quoting on the same product with different assumed regulatory routes will produce prices that look wildly different and cannot be compared.
2. Capacity utilisation has not been planned. Buyers frequently approach a CDMO with a launch quantity but no view of the twelve, twenty-four and thirty-six month volumes. Manufacturing economics are driven by batch size and line occupancy, not by the first order. A realistic utilisation plan changes which manufacturer is appropriate, what price is achievable, and whether the manufacturer will commit capacity at all. A small launch quantity with a credible growth plan often secures better terms than a larger one-off order.
3. The product has not been properly selected for the market. This is the most expensive of the three. Considerable effort goes into sourcing a molecule that turns out to face crowded local competition, an unfavourable reimbursement position, a strength or pack presentation the market does not use, or a registration timeline that arrives after the commercial opportunity has passed. Product selection is a market question that should be settled before it becomes a manufacturing question.
The practical implication: clarify the regulatory route, the volume plan and the product rationale first. Manufacturers respond faster and quote more sharply to a clear brief, and the selection criteria below become far easier to apply.
What a CDMO actually does
A Contract Development and Manufacturing Organisation handles some or all of the path from molecule to marketable product: formulation development, analytical method development, stability studies, scale-up, regulatory dossier preparation, and commercial manufacturing. A CMO (Contract Manufacturing Organisation) typically manufactures to your specification without the development component. In practice the terms blur, and many organisations offer both.
Buyers engage CDMOs for three broad reasons: they lack the manufacturing capability in-house, they lack capacity for a specific dosage form, or they want to enter a market without building a site there.
How the global CDMO market is structured
Rather than a single league table, it helps to think of the market in tiers and specialisms.
| Segment | What they offer | Typical fit |
|---|---|---|
| Large global biologics platforms | Mammalian and microbial manufacture at very large scale, cell and gene therapy, drug product and fill-finish | Innovators and biosimilar developers needing big capacity or complex modalities |
| Broad multi-stage platforms | API, oral solids, sterile injectables, biologics and clinical supply under one group | Companies wanting one partner across development stages |
| Drug-delivery specialists | Modified release, softgels, inhalation, drug-device combinations | Products where the delivery technology is the differentiator |
| European API and dosage-form specialists | Complex and high-potency APIs, sterile fill-finish, oral solids with strong regulatory footing | Regulated-market products where documentation and supply security matter most |
| Asian generic and formulation CDMOs | Oral solids, liquids, injectables and APIs at competitive cost, often with ready dossiers | Generics, private label and market-entry projects |
A structural point worth knowing in 2026: sterile fill-finish capacity remains scarce industry-wide. If your product is an injectable, capacity availability — not price — is usually the binding constraint, and lead times should be confirmed before anything else.
The India and Asia CDMO landscape
For buyers sourcing generics, finished formulations and APIs at commercial scale, India and the wider Asia region are where most volume is actually manufactured — and where cost structures make projects viable that would not be viable in the US or EU.
India has more US FDA–inspected manufacturing sites than any country other than the United States, and its manufacturers supply a substantial share of global generic volume. South Korea and China add very large biologics capacity. The practical implications for a sourcing decision:
- Dosage-form specialisation runs deep. Individual sites often specialise narrowly — oral solids, ophthalmics, injectables, transdermals, hormones — rather than offering everything.
- Regulatory coverage varies enormously by site. A company may hold US FDA approval for one facility and only WHO-GMP for another. Approval is site-specific and product-specific, never company-wide.
- Dossier availability is often the real asset. Many manufacturers hold ready CTD, EU-CTD or ACTD dossiers with bioequivalence data completed — which can compress a market-entry timeline from years to months.
- Minimum order quantities are typically lower than with the largest global platforms, making them accessible for smaller launches and single-market entries.
For more detail, see our guide to finding and qualifying a CDMO in India.
How to choose: the questions that actually matter
Global rank is a poor selection criterion. These seven questions determine whether a partnership works.
1. Does the site hold the right approval for your target market?
Ask for the specific facility's regulatory status — US FDA, EU-GMP, WHO-GMP, ANVISA, TGA, PMDA — and the date of the last inspection. Confirm the approval covers the dosage form you need, at that specific site. A company-level claim means nothing; approvals attach to facilities and product lines.
2. Have they manufactured this dosage form at your scale before?
A site that runs 50 million tablets a month is a different proposition from one running pilot batches. Ask for comparable batch sizes and comparable products, not a general capability statement.
3. What is the realistic capacity and lead time?
Capacity on paper differs from capacity available to you. Ask when a slot actually opens, and what the commitment terms are. For sterile injectables in particular, expect this to be the constraint.
4. Who owns the dossier and the intellectual property?
Establish before contracting whether you receive the dossier, whether it can be filed in your name, whether it is exclusive to you, and what happens on termination. This single point causes more disputes than any other.
5. What analytical and stability data will you receive?
Confirm the certificate of analysis format, the stability protocol and duration, and whether the data package meets your target market's filing requirements.
6. What is the quality track record?
Ask directly for recent inspection outcomes, any Form 483 observations or warning letters, and how they were resolved. A manufacturer that answers this openly is usually the safer partner.
7. Can they support your regulatory filing?
Registration support, market-specific documentation, legalisation and apostille of documents, and responsiveness to regulator queries during review are worth more than a small unit-price advantage.
Due-diligence red flags
- Reluctance to name the specific manufacturing site or to share the GMP certificate
- Approval claims that cannot be verified against the issuing authority's records
- Pricing far below market with no explanation of the cost structure
- Unwillingness to permit an audit, physical or virtual
- No named regulatory contact, or communication only through intermediaries
- Vague answers on dossier ownership
Working with a CDMO through a marketplace
Most buyers approach CDMO selection by contacting companies individually and repeating the same qualification conversation each time. A marketplace shortens this: you describe the project once — molecule, dosage form, volume, target market, regulatory need — and receive responses only from manufacturers whose site approvals and capacity actually match.
PharmaTradz works with GMP-certified manufacturers and CDMO partners across oral solids, injectables and pre-filled syringes, liquids and topicals, biologics fill-finish and nutraceuticals, at EU-GMP, US FDA, WHO-GMP, ANVISA and TGA-approved sites. Certifications are verified at onboarding rather than taken on trust.
See our sterile injectable and tablet contract manufacturing pages, or post your project requirement to be matched with manufacturers able to deliver it.
Frequently Asked Questions(FAQs)
What is the difference between a CMO and a CDMO?
A CMO manufactures a product to a specification you provide. A CDMO additionally offers development services — formulation development, analytical methods, stability studies, scale-up and regulatory dossier preparation. If you already hold a validated process and dossier, a CMO may be sufficient. If you are developing a product or entering a new market, a CDMO's development capability is usually necessary.
Is the largest CDMO the best choice?
Rarely on size alone. The largest platforms suit very large-scale or complex biologics work. For most generic, private-label and market-entry projects, dosage-form specialisation, site-level regulatory approval, dossier availability and available capacity matter far more than global rank.
How do I verify a CDMO's GMP certification?
Request the GMP certificate for the specific manufacturing site, then verify it against the issuing authority's public database — EudraGMDP for EU-GMP, the FDA inspection database for US FDA, or the relevant national regulator. Confirm that the certificate covers the dosage form you intend to manufacture and that it is current. Approvals are site-specific and product-specific.
Why do buyers choose CDMO services in India?
India has more US FDA–inspected manufacturing sites than any country other than the United States and supplies a significant share of global generic volume. Buyers typically cite cost structure, deep dosage-form specialisation, lower minimum order quantities and the availability of ready CTD, EU-CTD and ACTD dossiers, which can shorten market-entry timelines.
What should be agreed before signing a CDMO contract?
Dossier and intellectual property ownership, exclusivity terms, minimum order quantities, lead times and capacity commitment, the analytical and stability data package, the quality agreement and audit rights, regulatory filing support, and what happens to the dossier and inventory on termination.
How long does CDMO product development take?
For a generic product where a dossier already exists, technology transfer and commercial supply can take a few months. For a product requiring formulation development, bioequivalence studies and a fresh dossier, expect eighteen months to three years depending on the dosage form and target market.
